Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus

Journal of Vascular Surgery

Volumn 56, Issue 6, 2012, Pages 1680-1688

  Zhao, Hugh Q ^a   Nikanorov, Alexander ^a   Virmani, Renu ^b   Schwartz, Lewis B ^a  

^a ABBOTT LABORATORIES   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ETHYLENE VINYL ALCOHOL COPOLYMER; EVEROLIMUS; NITINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENIC CHANGE SCORE; ATHEROSCLEROSIS; BARE METAL STENT; CONTROLLED STUDY; DEVICE THERAPY; DRUG ELUTING STENT; HISTOLOGY; MORPHOMETRICS; NEOATHEROSCLEROSIS; NEOINTIMAL HYPERPLASIA; NITINOL STENT; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; SELF EXPANDING STENT;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; ILIAC ARTERY; IMMUNOSUPPRESSIVE AGENTS; NEOINTIMA; SIROLIMUS; SWINE; SWINE, MINIATURE;

EID: 84870245594     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2012.04.022     Document Type: Article

References (39)

1. C.J. Murray, A.D. Lopez Mortality by cause for eight regions of the world: Global Burden of Disease Study Lancet 349 1997 1269 1276
2. J.R. Laird Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries J Endovasc Ther 13 Suppl 2 2006 II30 II40
3. P.W. Serruys, M.J. Kutryk, A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495
4. M. Bosiers, D. Scheinert, P. Peeters, G. Torsello, T. Zeller, K. Deloose Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease J Vasc Surg 55 2012 390 398
5. D. Karnabatidis, S. Spiliopoulos, A. Diamantopoulos, K. Katsanos, G.C. Kagadis, S. Kakkos Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia J Endovasc Ther 18 2011 1 12
6. P.J. Houghton Everolimus Clin Cancer Res 16 2010 1368 1372
7. A.J. Carter, A. Brodeur, R. Collingwood, S. Ross, L. Gibson, C.A. Wang Experimental efficacy of an everolimus eluting cobalt chromium stent Catheter Cardiovasc Interv 68 2006 97 103
8. R. Waksman, R. Pakala, R. Baffour, D. Hellinga, R. Seabron, F. Kolodgie Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries Cardiovasc Revasc Med 7 2006 179 184
9. G.W. Stone, M. Midei, W. Newman, M. Sanz, J.B. Hermiller, J. Williams Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 16 2008 1903 1913
10. J. Lammer, D. Scheinert, F. Vermassen, R. Koppensteiner, K.A. Hausegger, H. Schroë Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature J Vasc Surg 55 2012 400 405
11. K. Budde, H.-H. Neumayer, G. Lehne, M. Winkler, I.A. Hauser, A. Lison Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients Nephrol Dial Transplant 19 2004 2606 2614
12. J.M. Kovarik, B.D. Kahan, B. Kaplan, M. Lorber, M. Winkler, M. Rouilly Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine Clin Pharmacol Ther 69 2001 48 56
13. H.H. Neumayer, K. Paradis, A. Korn, C. Jean, L. Fritsche, K. Budde Entry-into-human study with the novel immunosuppressant SDZ RAD (everolimus) in stable renal transplant recipients Br J Pharmacol 48 1999 694 703
14. U. Baber, R. Mehran, S.K. Sharma, S. Brar, J. Yu, J.-W. Suh Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials J Am Coll Cardiol 58 2011 1569 1577
15. S.H. Duda, M. Bosiers, J. Lammer, D. Scheinert, T. Zeller, V. Oliva Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial J Endovasc Ther 13 2006 701 710
16. M.D. Dake, G.M. Ansel, M.R. Jaff, T. Ohki, R.R. Saxon, H.B. Smouse Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results Circ Cardiovasc Interv 4 2011 495 504
17. Dake MD. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Hollywood, FL: International Society for Endovascular Therapy.
18. O. Iida, S. Nanto, M. Uematsu, K. Ikeoka, S. Okamoto, S. Nagata Influence of stent fracture on the long-term patency in the femoro-popliteal artery: Experience of 4 years JACC Cardiovasc Interv 2 2009 665 671
19. J.R. Laird, B.T. Katzen, D. Scheinert, J. Lammer, J. Carpenter, M. Buchbinder Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial Circ Cardiovasc Interv 3 2010 267 276
20. Y. Soga, O. Iida, K. Hirano, H. Yokoi, S. Nanto, M. Nobuyoshi Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent J Vasc Surg 52 2010 608 615
21. D.K. Han, T.R. Shah, S.H. Ellozy, A.G. Vouyouka, M.L. Marin, P.L. Faries The success of endovascular therapy for all TransAtlantic Society Consensus graded femoropopliteal lesions Ann Vasc Surg 25 2011 15 24
22. M.D. Dake, W.G. Van Alstine, Q. Zhou, A.O. Ragheb Polymer-free paclitaxel-coated Zilver PTX stents - Evaluation of pharmacokinetics and comparative safety in porcine arteries J Vasc Interv Radiol 22 2011 603 610
23. H.Q. Zhao, D. Jayasinghe, S. Hossainy, L.B. Schwartz A theoretical model to characterize the drug release behavior of drug-eluting stents with durable polymer matrix coating J Biomed Mater Res A 100 2012 120 124
24. A.J. Carter, M. Aggarwal, G.A. Kopia, F. Tio, P.S. Tsao, R. Kolata Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model Cardiovasc Res 63 2004 617 624
25. G. Nakazawa, A.V. Finn, M.C. John, F.D. Kolodgie, R. Virmani The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents Am J Cardiol 100 2007 36M 44M
26. G.J. Wilson, G. Nakazawa, R.S. Schwartz, B. Huibregtse, B. Poff, T.J. Herbst Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries Circulation 120 2009 141 149
27. G. Nakazawa, F. Otsuka, M. Nakano, M. Vorpahl, S.K. Yazdani, E. Ladich The pathology of neoatherosclerosis in human coronary implants: Bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
28. M.G. Davies, P.O. Hagen Reprinted article "Pathophysiology of vein graft failure: A review" Eur J Vasc Endovasc Surg 42 Suppl 1 2011 S19 S29
29. S. Semsroth, R.G. Stigler, O.Y. Bernecker, E. Ruttmann-Ulmer, J. Troppmair, K. Macfelda Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts Eur J Cardiothorac Surg 35 2009 515 520
30. A. Farb, M. John, E. Acampado, F.D. Kolodgie, M.F. Prescott, R. Virmani Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384
31. M.I. Lorber, S. Mulgaonkar, K.M. Butt, E. Elkhammas, R. Mendez, P.R. Rajagopalan Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study Transplantation 80 2005 244 252
32. H.J. Eisen, E.M. Tuzcu, R. Dorent, J. Kobashigawa, D. Mancini, H.A. Valantine-von Kaeppler Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858
33. K.W. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 2006 5165 5173
34. S. Oudard, J. Medioni, J. Ayllon, E. Barrascourt, R.T. Elaidi, J. Balcaceres Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma Expert Rev Anticancer Ther 9 2009 705 717
35. T. Grgic, L. Mis, J.M. Hammond Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma Ann Pharmacother 45 2011 78 83
36. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
37. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
38. P.W. Serruys, J.A. Ormiston, Y. Onuma, E. Regar, N. Gonzalo, H.M. Garcia-Garcia A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
39. J. Lammer, M. Bosiers, T. Zeller, M. Schillinger, E. Boone, M.J. Zaugg First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease J Vasc Surg 54 2011 394 401